Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 1/20 | 0.61 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | ELANE | P08246 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | CTSS | P25774 | 1/20 | 0.31 |
| ▸ | CTSK | P43235 | 1/20 | 0.31 |
| ▸ | USP2 | O75604 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3141601 | 0.85 | DGAT1 (0.79) | DGAT1TSHRALDH1A1ELANEMEN1 | |
| SCHEMBL16787839 | 0.78 | DGAT1 (0.61) | DGAT1GAAUSP2SMN1; SMN2 | |
| Hydrogen Peroxide SCHEMBL25411902 | 0.77 | DGAT1 (0.52) | DGAT1TSHRALDH1A1ELANEMEN1 | |
| SCHEMBL9067049 | 0.77 | TSHR (0.42) | DGAT1TSHRALDH1A1ELANECYP2D6 | |
| SCHEMBL9784263 | 0.76 | DGAT1 (0.58) | DGAT1 | |
| SCHEMBL13904644 | 0.76 | DGAT1 (0.46) | DGAT1TSHRALDH1A1MEN1GAA | |
| SCHEMBL1735445 | 0.76 | DGAT1 (1.00) | DGAT1ALDH1A1ELANEMEN1GAA | |
| SCHEMBL29798821 | 0.75 | DGAT1 (0.37) | DGAT1TSHRALDH1A1ELANECYP2D6 | |
| SCHEMBL1010735 | 0.74 | DGAT1 (0.56) | DGAT1TSHRALDH1A1ELANECYP2D6 | |
| SCHEMBL1486198 | 0.74 | DGAT1 (0.44) | DGAT1TSHRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113527281-B | Heterocyclic compounds, process for their preparation and their use | 昆山彭济凯丰生物科技有限公司 | 2023-12-22 | — | — | CN | disclosed |
| US-20230400766-A1 | ONIUM SALT, RESIST COMPOSITION AND PATTERN FORMING PROCESS | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2023-12-14 | — | — | US | disclosed |
| US-20230330254-A1 | ANTI-GLP1R ANTIBODY-TETHERED DRUG CONJUGATES COMPRISING GLP1 PEPTIDOMIMETICS AND USES THEREOF | REGENERON PHARMACEUTICALS, INC. (US) | 2023-10-19 | — | — | US | disclosed |
| US-20230330254-A1 | ANTI-GLP1R ANTIBODY-TETHERED DRUG CONJUGATES COMPRISING GLP1 PEPTIDOMIMETICS AND USES THEREOF | REGENERON PHARMACEUTICALS, INC. (US) | 2023-10-19 | — | — | US | disclosed |
| CN-113527281-A | Heterocyclic compounds, their preparation and use | 昆山彭济凯丰生物科技有限公司 | 2021-10-22 | — | — | CN | disclosed |
| US-9963454-B2 | Compounds and compositions for the treatment of parasitic disease | NOVARTIS AG (CH) | 2018-05-08 | — | — | US | disclosed |
| US-9469645-B2 | Compounds and compositions for the treatment of parasitic diseases | NOVARTIS AG (CH) | 2016-10-18 | — | — | US | disclosed |
| US-20160120878-A1 | DERIVATIVES OF BETULIN | GLAXOSMITHKLINE LLC | 2016-05-05 | — | — | US | disclosed |
| US-20160120878-A1 | DERIVATIVES OF BETULIN | GLAXOSMITHKLINE LLC | 2016-05-05 | — | — | US | disclosed |
| US-20160108051-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASE | NOVARTIS AG (CH) | 2016-04-21 | — | — | US | disclosed |
| US-5698569-A | Retroviral protease inhibitors | G. D. SEARLE & CO. (US) | 1997-12-16 | — | — | US | disclosed |
| US-5622949-A | AIDS THERAPY | G. D. SEARLE & CO. (US) | 1997-04-22 | — | — | US | disclosed |
| US-5620977-A | HUMAN IMMUNODEFICIENCY VIRUS | G.D. SEARLE & CO. (US) | 1997-04-15 | — | — | US | disclosed |
| US-5614522-A | SULFONAMIDE AND UREA-CONTAINING HYDROXYETHYLAMINE COMPOUNDS | G.D. SEARLE & CO. (US) | 1997-03-25 | — | — | US | disclosed |
| EP-0558673-B1 | RETROVIRAL PROTEASE INHIBITORS | MONSANTO CO (US) | 1996-04-17 | — | — | EP | disclosed |
| US-5475013-A | Inhibit human immunodeficiency virus protease | MONSANTO COMPANY (US) | 1995-12-12 | — | — | US | disclosed |
| EP-0558603-A1 | RETROVIRAL PROTEASE INHIBITORS | MONSANTO COMPANY (US) | 1993-09-08 | — | — | EP | disclosed |
| EP-0558673-A1 | RETROVIRAL PROTEASE INHIBITORS. | MONSANTO CO (US) | 1993-09-08 | — | — | EP | disclosed |
| WO-1992008699-A1 | RETROVIRAL PROTEASE INHIBITORS | MONSANTO COMPANY (US) | 1992-05-29 | — | — | WO | disclosed |
| WO-1992008688-A1 | RETROVIRAL PROTEASE INHIBITORS | MONSANTO COMPANY (US) | 1992-05-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160108051-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASE | SQLE, SGMS2, SGMS1 | DGAT1 548/4885TSHR 4563/4885ALDH1A1 2013/4885 |
| US-20230330254-A1 | ANTI-GLP1R ANTIBODY-TETHERED DRUG CONJUGATES COMPRISING GLP1 PEPTIDOMIMETICS AND USES THEREOF | GLP1R, GIPR, GCGR | DGAT1 325/4885TSHR 127/4885ALDH1A1 1481/4885 |
| US-20160120878-A1 | DERIVATIVES OF BETULIN | BET1, PGGT1B, TMPO | DGAT1 2984/4885TSHR 4549/4885ALDH1A1 2729/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.